EKSO

#4426
Ekso Bionics Holdings, Inc. Common Stock
11.3700 USD
+1.70%
부문: 헬스케어
베이스: USD
수익 통화: USD
일일 변동 비율
11.3700
11.3700
년간 변동
7.8900
13.5000
일일 변동
+1.70%
월간 변동
+13.59%
6달 변화
-9.19%
년간 변동율
-9.19%
이전 종가
11.1800
시가
11.3700
저가
11.3700
High
11.3700
양
1
전체 차트 열기

Financials

개요 성명 통계
4분기 연간
  • Market Capitalization 40.5156 M
  • Employee 55
  • Founded 2005
  • CEO Scott Davis
  • Website www.eksobionics.com
  • Headquarter Nevada, United States
  • FIGI BBG002Z0NKK4
  • Industry 의료기기 & 의료용 소모품
총매출
순이익
주당 순이익(기본 EPS)
총부채
잉여 현금 흐름
현금 및 현금성 자산
주가수익비율
-1.76
주가매출액비율
1.64

Ekso Bionics Holdings Inc

Ekso Bionics Holdings Inc. is a company that develops and manufactures powered exoskeleton bionic devices that can be strapped on as wearable robots to enhance the strength, mobility, and endurance of industrial workers and people experiencing paralysis and mobility issues after a brain injury, stroke, multiple sclerosis or spinal cord injury. They enable individuals with any amount of lower extremity weakness, including those who are paralyzed, to stand up and walk. Ekso Bionics currently focuses in the health and industrial sectors. The company's first commercially available health product was called EksoGT. Ekso Bionics is the original developer of HULC, now under military development by Lockheed Martin, and the current developers of EksoNR, which allows patients who are relearning to walk the ability to stand and take steps. In December 2022, Ekso Bionics acquired the Human Motion & Control business unit from Parker Hannifin which includes the Indego product line. This acquisition allowed Ekso Bionics to begin selling exoskeletons to those who have an SCI and want a personal exoskeleton to walk at home and in their community.

뉴스